A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1820-1829

  Zhang, Yong ^a,d   Shaik, Ahmad Ali ^a   Xing, Chengguo ^a   Chai, Yubo ^a   Li, Li ^a,d   Zhang, Jinhui ^a,d   Zhang, Wei ^b   Kim, Sung Hoon ^a,c   Lü, Junxuan ^a,d   Jiang, Cheng ^a,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c Kyung Hee University   (South Korea)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Androgen receptor; Decursin; Prostate cancer; Stable derivative

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; DECURSIN; DECURSINOL ANGELATE; DECURSINOL PHENYLTHIOCARBAMATE; MESSENGER RNA; PROBASIN; PROSTATE SPECIFIC ANTIGEN; STEROID HORMONE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOSIS INHIBITION; MOUSE; NKX3.1 GENE; NONHUMAN; PRIORITY JOURNAL; PROBASIN GENE; RECEPTOR BLOCKING;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; APOPTOSIS; BENZOPYRANS; BUTYRATES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DOWN-REGULATION; G1 PHASE; HUMANS; ISOTHIOCYANATES; MALE; MICE; MICE, INBRED C57BL; PHENYLCARBAMATES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RECEPTORS, ANDROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIOCARBAMATES;

EID: 84867842386     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9738-x     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 60(5):277-300
2. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25(2):276-308
3. Kung HJ, Evans CP (2009) Oncogenic activation of androgen receptor. Urol Oncol 27(1):48-52
4. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23(32):8253-8261
5. Petrylak DP (2005) The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65(5 Suppl):3-7, discussion 7-8
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nature medicine 10(1):33-39
7. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z (2007) A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res 35(8):2767-2776
8. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York) 324(5928):787-790
9. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27(23):3742-3748
10. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375(9724):1437-1446
11. Han D (1992) Pharmacognosy, 4th edn. Dongmyungsa Press, Seoul
12. Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, Lee EO, Lee JH, Kim MS, Kim SH, Lu J (2006) Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer research 66(1):453-463
13. Guo J, Jiang C, Wang Z, Lee HJ, Hu H, Malewicz B, Lee HJ, Lee JH, Baek NI, Jeong JH, Kim DK, Kang KS, Kim SH, Lu J (2007) A novel class of pyranocoumarin anti-androgen receptor signaling compounds. Mol Canc Therapeut 6(3):907-917
14. Lu J, Kim S, Jiang C, Lee H, Guo J (2007) Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents. Acta Pharmacol Sin 28(9):1365-1372
15. Yim D, Singh RP, Agarwal C, Lee S, Chi H, Agarwal R (2005) A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res 65(3):1035-1044
16. Lee HJ, Lee EO, Lee JH, Lee KS, Kim KH, Kim SH, Lu J (2009) In vivo anti-cancer activity of Korean Angelica gigas and its major pyranocoumarin decursin. Am J Chin Med 37(1):127-142
17. Song GY, Lee JH, Cho M, Park BS, Kim DE, Oh S (2007) Decursin suppresses human androgen-independent PC3 prostate cancer cell proliferation by promoting the degradation of beta-catenin. Mol Pharmacol 72(6):1599-1606
18. Kim WJ, Lee SJ, Choi YD, Moon SK (2010) Decursin inhibits growth of human bladder and colon cancer cells via apoptosis, G1-phase cell cycle arrest and extracellular signal-regulated kinase activation. Int J Mol Med 25(4):635-641
19. Jiang C, Guo J, Wang Z, Xiao B, Lee HJ, Lee EO, Kim SH, Lu J (2007) Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells. Breast Cancer Res 9(6):R77
20. Lee S, Lee YS, Jung SH, Shin KH, Kim BK, Kang SS (2003) Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch Pharm Res 26(9):727-730
21. Kim HH, Sik Bang S, Seok Choi J, Han H, Kim IH (2005) Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells. Cancer letters 223(2):191-201
22. Park R, Kim N, Lee K, Seo S (2001) Comparative studies on concentration of decursinol in plasma after oral administration of Angelica gigantis radix extract and combined use of decursin and Cnidii rhizoma extract or Bupleuri radix extract in rats. Korean J Pharmacogn 32(72-78)
23. Lee S, Kang S, Shin K (2002) Coumarins and a pyrimidine from Angelica gigas roots. Nat Product Sci 8:58-61
24. Kang Y, Lee J, Chae H, Kim D, Lee S, Park S (2003) HPLC analysis and extraction method of decursin and decursinol angelate in A. gigas roots. Korean J Pharmacol 34:201-205
25. Li L, Zhang J, Shaik A, Zhang Y, Wang L, Xing C, Kim S, Lü J (2011) Determination of decursin, decursinol angelate and decursinol simultaneously in mouse plasma and tumor tissue by liquid-liquid extraction and HPLC. J Pharm Biomed Anal. Submitted
26. Cho SD, Jiang C, Malewicz B, Dong Y, Young CY, Kang KS, Lee YS, Ip C, Lu J (2004) Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Canc Therapeut 3(5):605-611
27. Xu LL, Srikantan V, Sesterhenn IA, Augustus M, Dean R, Moul JW, Carter KC, Srivastava S (2000) Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol 163(3):972-979
28. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, et al. (1993) Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 7(1):23-36
29. Zhang Y, Kim KH, Zhang W, Guo Y, Kim SH, Lu J (2011 Feb 15) [Epub ahead of print]) Galbanic acid decreases androgen receptor abundance and signaling and induces G(1) arrest in prostate cancer cells. Int J Cancer. doi: 10.1002/ijc.25993
30. Malewicz B, Wang Z, Jiang C, Guo J, Cleary MP, Grande JP, Lü J (2006) Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements. Carcinogenesis 27(9):1739-1747
31. Maestro, version 9.0 (2009) Schrödinger, LLC, New York, NY
32. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49(2):534-553
33. Glide, version 5.0 (2009). Schrödinger, LLC, New York, NY
34. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP (2002) Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277(29):26321-26326
35. Fu R, Liu J, Fan J, Li R, Li D, Yin J, Cui S (2011) Novel evidence that testosterone promotes cell proliferation and differentiation via G protein-coupled receptors in the rat L6 skeletal muscle myoblast cell line. J Cell Physiol. doi: 10.1002/jcp.22710, [Epub ahead of print]. Mar 3